---
title: "VK2735 in Chronic weight management: Long-term morbidity"
description: "Formulary evidence on VK2735 in Chronic weight management: Long-term morbidity. Topics: Incidence of 18 comorbidities: systematic review and meta-analysis, Obesity-related multimorbidity: Finnish cohorts and UK Biobank, Cardiovascular disease: heart failure and atrial fibrillation, Cancer: sites with sufficient evidence for excess body fatness, and 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Incidence of 18 comorbidities: systematic review and meta-analysis

> “Statistically significant associations with obesity were found with the incidence of type II diabetes, all cancers except esophageal and prostate cancer, all cardiovascular diseases, asthma, gallbladder disease, osteoarthritis and chronic back pain.”
> “Obesity defined by BMI was also most strongly associated with the incidence of type II diabetes in females (12.41 (9.03–17.06)).”

Source: [Guh et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2667420/)

<a id="topic-2.2.1.7-2"></a>

### Obesity-related multimorbidity: Finnish cohorts and UK Biobank

> “Obesity was associated with 21 non-overlapping cardiometabolic, digestive, respiratory, neurological, musculoskeletal, and infectious diseases after Bonferroni multiple testing adjustment and ignoring HRs of less than 1·50.”
> “Compared with healthy weight, the confounder-adjusted HR for obesity was 2·83 (95% CI 2·74–2·93; PAF 19·9% [95% CI 19·3–20·5]) for developing at least one obesity-related disease, 5·17 (4·84–5·53; 34·4% [33·2–35·5]) for two diseases, and 12·39 (9·26–16·58; 55·2% [50·9–57·5]) for complex multimorbidity.”
> “The proportion of participants of healthy weight with complex multimorbidity by age 75 years was observed by age 55 years in participants with obesity”

Source: [Kivimäki et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8938400/)

<a id="topic-2.2.1.7-3"></a>

### Cardiovascular disease: heart failure and atrial fibrillation

> “In a study of 5881 Framingham Heart Study participants, HF incidence increased by 5% in men and 7% in women for every 1-unit BMI increase after adjustment for other risk factors, and the risk of HF increased across the entire spectrum of BMI.”
> “Recent work has also suggested that higher BMI is more strongly associated with the risk of HFpEF than with HFrEF.”
> “Several prospective epidemiological studies demonstrate that obesity is associated with higher risk of incident coronary artery disease (CAD).”
> “Overweight and obesity elevate the risk of AF through numerous mechanisms, including structural and electric remodeling, which contribute to development of the arrhythmogenic substrate”

Source: [Powell-Wiley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8493650/)

<a id="topic-2.2.1.7-4"></a>

### Cancer: sites with sufficient evidence for excess body fatness

> “Furthermore, we identified an additional eight cancers for which there is now also sufficient evidence that the absence of body fatness lowers cancer risk, including cancers of the gastric cardia, liver, gallbladder, pancreas, ovary, and thyroid, as well as multiple myeloma and meningioma.”
> “There was a strong dose–response relationship, with relative risks of approximately 1.5 for overweight, 2.5 for class 1 obesity, 4.5 for class 2 obesity, and 7.1 for class 3 obesity.”

Source: [Lauby-Secretan et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6754861/)

> “Obesity is associated with increased risk for 13 types of cancer that account for more than 40% of cancer diagnoses annually.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.7-5"></a>

### Knee osteoarthritis: meta-analysis of prospective studies

> “The results showed that overweight and obesity were significantly associated with higher knee OA risks of 2.45 (95% CI 1.88 to 3.20, p<0.001) and 4.55 (95% CI 2.90 to 7.13, p<0.001), respectively.”
> “The risk of knee OA increases by 35% (95% CI 1.18 to 1.53, p<0.001) with a 5 kg/m2 increase in BMI.”

Source: [Zheng and Chen (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4679914/)

<a id="topic-2.2.1.7-6"></a>

### Sleep-disordered breathing: prevalence in United States adults

> “Obesity is a strong causal factor for sleep-disordered breathing, and because of the ongoing obesity epidemic, previous estimates of sleep-disordered breathing prevalence require updating.”
> “The current prevalence estimates of moderate to severe sleep-disordered breathing (apnea-hypopnea index, measured as events/hour, ≥15) are 10% (95% confidence interval (CI): 7, 12) among 30–49-year-old men; 17% (95% CI: 15, 21) among 50–70-year-old men; 3% (95% CI: 2, 4) among 30–49-year-old women; and 9% (95% CI: 7, 11) among 50–70 year-old women.”

Source: [Peppard et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3639722/)

<a id="topic-2.2.1.7-7"></a>

### Liver and kidney disease: MASLD and obesity-related glomerulopathy

> “Deposition of ectopic fat in the liver among susceptible individuals can lead to the development of MASLD.”
> “Once MASLD progresses beyond steatosis to steatohepatitis with fibrosis, there is substantial risk of cirrhosis, liver failure, and hepatocellular carcinoma.”
> “The development of obesity-related glomerulopathy is well recognised and can lead to end-stage kidney disease.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

<a id="topic-2.2.1.7-8"></a>

### Type 2 diabetes: progressive beta-cell dysfunction

> “Individuals predisposed to glucotoxicity and lipotoxicity of β cells have a gradual decline in insulin secretion, which becomes insufficient for normal metabolism of glucose, proteins, and lipids.”
> “Higher levels of adiposity worsen insulin resistance, increasing β-cell demand, particularly when fat is deposited ectopically in the liver and muscle.”

Source: [Rubino et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11870235/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
